Tufts CSDD Demonstrates Multi-Million-Dollar Benefits of Translational Pharmaceutics®
6 / 56 articles displayed
News
Quotient Sciences, the innovative drug development and manufacturing organization, today announces the appointment of Claes Glassell as non‐executive chairman of its board of directors. A highly accomplished leader in the pharmaceutical industry with over 35 years’ experience, Glassell has held numerous leadership positions, including at the board level, to help companies through high phases of growth.
News
Quotient Sciences to Recapitalize With Global Private Equity Firm Permira
News
Quotient’s Andy Lewis appointed as Secretary of Controlled Release Society
News
Quotient Sciences has won the Outstanding Achievement Award at the 2019 Medilink UK Healthcare Business Awards.
Awards
Quotient Sciences announced that it has received a Transatlantic Growth Award at a ceremony hosted by BritishAmerican Business in London. The award, in the 'UK SME in the US' category, was presented to Gordon Cameron, CFO, Quotient Sciences.
News
Quotient Sciences, and Druggability Technologies (DRGT), a specialty pharmaceutical company, announced a collaboration today to utilize Quotient’s integrated Translational Pharmaceutics® platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT. This will be Quotient’s first Translational Pharmaceutics program delivered from its U.S. operating facilities.
Ask us a question
